COMT on Aspirin Platelets Effects (CAPE)

Status unconfirmed · Phase 4 · Has a placebo group

Conditions studied: Cardiovascular Diseases

In brief

Specific Aim I: Examine the role of genetic variation in COMT on platelet function in a blinded, randomized, placebo controlled clinical trial of daily placebo or Aspirin (81mg) for 10 ± 3 days. Platelet function will be assessed with platelet aggregometry and by fluorescence-activated cell sorting (FACS) of platelet adhesion molecules P-selectin and GPIIb/IIIa in platelets activated with arachidonic acid, thrombin, collagen, epinephrine and ADP. Specific Aim II: Examine the effects of platelet releasates harvested at the end of each treatment arm on angiogenesis.

Key facts

Study ID

NCT03433586

Run by

Brigham and Women's Hospital

People needed

45

Starts

2020-07-10

Expected to finish

2022-04-30

Last updated by the study team

2021-06-25

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• healthy, 18-40 years

You may not qualify if…

• taking aspirin. Smoking, pregnancy, history of cancer of cardiovascular disease. Mental illness.

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.